We are live on
!
Find out more
Atossa Therapeutics
ATOS
ATOS
54 hedge funds and large institutions have $11.9M invested in Atossa Therapeutics in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 15 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
850% more call options, than puts
Call options by funds: $779K | Put options by funds: $82K
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
4% more funds holding
Funds holding: 52 → 54 (+2)
0.01% more ownership
Funds ownership: 0.84% → 0.86% (+0.01%)
20% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 15
41% less capital invested
Capital invested by funds: $20.2M → $11.9M (-$8.26M)
Holders
54
Holders Change
+2
Holders Change %
+3.85%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
12
Reduced
15
Closed
6
Calls
$779K
Puts
$82K
Net Calls
+$697K
Net Calls Change
-$594K
Top Buyers
Top Sellers
| 1 |
D.E. Shaw & Co
New York
|
-$273K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$120K |
| 3 |
Millennium Management
New York
|
-$74.2K |
| 4 |
Jane Street
New York
|
-$59.6K |
| 5 |
Morgan Stanley
New York
|
-$44.6K |
